Stroke prevention in nonvalvular atrial fibrillation

Texas Heart Institute Journal

Volumn 38, Issue 4, 2011, Pages 350-352

  Ganjehei, Leila ^a   Massumi, Ali ^a   Razavi, Mehdi ^a   Rasekh, Abdi ^a  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; ESTERASE; PLACEBO; WARFARIN;

ARTICLE; BLEEDING; BRAIN ISCHEMIA; DEVICE THERAPY; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; EMBOLISM; ENZYME PRODRUG THERAPY; FOOD; FOOD DRUG INTERACTION; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HUMAN; LEFT ATRIAL APPENDAGE; NONHUMAN; PATIENT COMPLIANCE; RECOMMENDED DRUG DOSE; STROKE; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CARDIAC SURGICAL PROCEDURES; HEART CATHETERIZATION; HUMANS; PREVENTIVE HEALTH SERVICES; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 80051815701     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123(10):e269-367.
2. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association [published erratum appears in Circulation 2011;123(6):e240]. Circulation 2011;123(4):e18-e209.
3. Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27(10):1760-4.
4. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61(2):755-9.
5. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009;373(9658):155-66.
6. Johnson WD, Ganjoo AK, Stone CD, Srivyas RC, Howard M. The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardiothorac Surg 2000;17 (6):718-22.
7. Odell JA, Blackshear JL, Davies E, Byrne WJ, Kollmorgen CF, Edwards WD, Orszulak TA. Thoracoscopic obliteration of the left atrial appendage: potential for stroke reduction? Ann Thorac Surg 1996;61(2):565-9.
8. Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005;150(2):288-93.
9. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347(23):1825-33.
10. Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006;166(12):1269-75.
11. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131(7):492-501.
12. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [published erratum appears in Circulation 2007;116(6):e138]. Circulation 2006;114(7): e257-354.
13. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res 2006;118(3):321-33.
14. Dharmarajan TS, Varma S, Akkaladevi S, Lebelt AS, Norkus EP. To anticoagulate or not to anticoagulate? A common dilemma for the provider: physicians' opinion poll based on a case study of an older long-term care facility resident with dementia and atrial fibrillation. J Am Med Dir Assoc 2006;7(1): 23-8.
15. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167(3):239-45.
16. Amouyel P, Mismetti P, Langkilde LK, Jasso-Mosqueda G, Nelander K, Lamarque H. INR variability in atrial fibrillation: a risk model for cerebrovascular events. Eur J Intern Med 2009;20(1):63-9.
17. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation [published erratum appears in N Engl J Med 2010;363(19):1877]. N Engl J Med 2009;361(12):1139-51.
18. Fountain RB, Holmes DR, Chandrasekaran K, Packer D, Asirvatham S, Van Tassel R, Turi Z. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J 2006;151(5):956-61.
19. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial f ibrillation: a randomised non-inferiority trial [published erratum appears in Lancet 2009;374(9701):1596]. Lancet 2009;374(9689):534-42.
20. Gorodnitskiy A, Lucariello RJ, Aizer A, Coppola JT. A novel approach to left atrial appendage exclusion: the WATCHMAN device. Cardiol Rev 2010;18(5):230-3.
21. Meier B, Palacios I, Windecker S, Rotter M, Cao QL, Keane D, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv 2003;60(3):417-22.
22. Park JW, Bethencourt A, Sievert H, Santoro G, Meier B, Walsh K, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv 2011;77(5):700-6.
23. Bartus K, Bednarek J, Myc J, Kapelak B, Sadowski J, Lelakowski J, et al. Feasibility of closed-chest ligation of the left atrial appendage in humans. Heart Rhythm 2011;8(2):188-93.
24. Lee RJ, Bartus K, Yakubov SJ. Catheter-based left atrial appendage (LAA) ligation for the prevention of embolic events arising from the LAA: initial experience in a canine model. Circ Cardiovasc Interv 2010;3(3):224-9.